Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.

Mostrar todas las versiones(2)

Chagas disease (ChD) is caused by the flagellated parasite Trypanosoma cruzi (T. cruzi), representing a serious public health in Latin America. Currently, there are prevention measures such as blood screening, control of pregnant women and vector control, but more effective strategies are still requ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dinatale, Brenda, Bulfoni Balbi, Camila, González, Florencia B., Pérez, Ana Rosa, Pacini, María Florencia
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional de Rosario 2021
Materias:
Vacuna
Transialidasa
Enfermedad de Chagas
Vaccine
Trans—sialidase
Chagas disease
Acceso en línea:https://fcmcientifica.unr.edu.ar/index.php/revista/article/view/17
Aporte de:
FCM Científica de Universidad Nacional de Rosario
id I15-R235-article-17
record_format ojs
spelling I15-R235-article-172022-07-07T12:22:47Z Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease. Desarrollo preclínico de vacunas profilácticas contra la Enfermedad de Chagas basadas en Transialidasa. Dinatale, Brenda Bulfoni Balbi, Camila González, Florencia B. Pérez, Ana Rosa Pacini, María Florencia Vacuna Transialidasa Enfermedad de Chagas Vaccine Trans—sialidase Chagas disease Chagas disease (ChD) is caused by the flagellated parasite Trypanosoma cruzi (T. cruzi), representing a serious public health in Latin America. Currently, there are prevention measures such as blood screening, control of pregnant women and vector control, but more effective strategies are still required to prevent new cases. One of these strategies is the development of a prophylactic vaccine against T. cruzi. Since the discovery of the disease in 1909, different experimental vaccines have been evaluated, but the clinical development of an effective formulation against the parasite has not yet been achieved. Here, we review the different vaccination strategies that have been evaluated to date, and particularly, the use of the enzyme Trans—sialidase (TS) as a vaccine antigen. We also address different aspects of the TS superfamily, such as the classification of the different proteins, their functional characteristics, and their role in T. cruzi infection. Over 100 years, a great diversity of vaccine strategies against T. cruzi have been approached and refined, auguring that in the near future it will be possible to cross from the pre—clinical to the clinical field. La Enfermedad de Chagas (ECh), ocasionada por el parásito flagelado Trypanosoma cruzi (T. cruzi), es una de las parasitosis de mayor impacto en la Salud Pública de Latinoamérica. Si bien actualmente existen medidas de prevención como el tamizaje en bancos de sangre, el control a las embarazadas y el control vectorial, aún se requiere de estrategias más eficaces para evitar nuevos casos. Una de estas posibles estrategias es el desarrollo de una vacuna profiláctica contra T. cruzi. Desde el descubrimiento de la enfermedad en 1909, se han evaluado diferentes vacunas experimentales, pero aún no se ha logrado el desarrollo clínico de una formulación efectiva contra el parásito. En este artículo realizamos una revisión bibliográfica acerca de las distintas estrategias de vacunación que se evaluaron hasta la actualidad y, particularmente, el uso de la enzima Transialidasa (TS) como antígeno vacunal. También abordamos distintos aspectos de la superfamilia de la TS, como la clasificación de las distintas proteínas, sus características funcionales y su rol en la infección por T. cruzi. A lo largo de 100 años se han abordado y perfeccionado una gran diversidad de estrategias vacunales contra T. cruzi, lo cual permite augurar el salto desde el campo pre—clínico al desarrollo clínico de una vacuna efectiva en un futuro cercano. Universidad Nacional de Rosario 2021-06-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://fcmcientifica.unr.edu.ar/index.php/revista/article/view/17 10.35305/fcm.v1i.17 Revista de la Facultad de Ciencias Médicas. Universidad Nacional de Rosario.; Vol. 1 (2020); 23-38 2796-7719 spa https://fcmcientifica.unr.edu.ar/index.php/revista/article/view/17/34 https://creativecommons.org/licenses/by-nc/4.0/
institution Universidad Nacional de Rosario
institution_str I-15
repository_str R-235
container_title_str FCM Científica
language Español
format Artículo revista
topic Vacuna
Transialidasa
Enfermedad de Chagas
Vaccine
Trans—sialidase
Chagas disease
spellingShingle Vacuna
Transialidasa
Enfermedad de Chagas
Vaccine
Trans—sialidase
Chagas disease
Dinatale, Brenda
Bulfoni Balbi, Camila
González, Florencia B.
Pérez, Ana Rosa
Pacini, María Florencia
Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.
topic_facet Vacuna
Transialidasa
Enfermedad de Chagas
Vaccine
Trans—sialidase
Chagas disease
author Dinatale, Brenda
Bulfoni Balbi, Camila
González, Florencia B.
Pérez, Ana Rosa
Pacini, María Florencia
author_facet Dinatale, Brenda
Bulfoni Balbi, Camila
González, Florencia B.
Pérez, Ana Rosa
Pacini, María Florencia
author_sort Dinatale, Brenda
title Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.
title_short Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.
title_full Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.
title_fullStr Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.
title_full_unstemmed Pre—clinical development of Trans—sialidase based prophylactic vaccines against Chagas disease.
title_sort pre—clinical development of trans—sialidase based prophylactic vaccines against chagas disease.
description Chagas disease (ChD) is caused by the flagellated parasite Trypanosoma cruzi (T. cruzi), representing a serious public health in Latin America. Currently, there are prevention measures such as blood screening, control of pregnant women and vector control, but more effective strategies are still required to prevent new cases. One of these strategies is the development of a prophylactic vaccine against T. cruzi. Since the discovery of the disease in 1909, different experimental vaccines have been evaluated, but the clinical development of an effective formulation against the parasite has not yet been achieved. Here, we review the different vaccination strategies that have been evaluated to date, and particularly, the use of the enzyme Trans—sialidase (TS) as a vaccine antigen. We also address different aspects of the TS superfamily, such as the classification of the different proteins, their functional characteristics, and their role in T. cruzi infection. Over 100 years, a great diversity of vaccine strategies against T. cruzi have been approached and refined, auguring that in the near future it will be possible to cross from the pre—clinical to the clinical field.
publisher Universidad Nacional de Rosario
publishDate 2021
url https://fcmcientifica.unr.edu.ar/index.php/revista/article/view/17
work_keys_str_mv AT dinatalebrenda preclinicaldevelopmentoftranssialidasebasedprophylacticvaccinesagainstchagasdisease
AT bulfonibalbicamila preclinicaldevelopmentoftranssialidasebasedprophylacticvaccinesagainstchagasdisease
AT gonzalezflorenciab preclinicaldevelopmentoftranssialidasebasedprophylacticvaccinesagainstchagasdisease
AT perezanarosa preclinicaldevelopmentoftranssialidasebasedprophylacticvaccinesagainstchagasdisease
AT pacinimariaflorencia preclinicaldevelopmentoftranssialidasebasedprophylacticvaccinesagainstchagasdisease
AT dinatalebrenda desarrollopreclinicodevacunasprofilacticascontralaenfermedaddechagasbasadasentransialidasa
AT bulfonibalbicamila desarrollopreclinicodevacunasprofilacticascontralaenfermedaddechagasbasadasentransialidasa
AT gonzalezflorenciab desarrollopreclinicodevacunasprofilacticascontralaenfermedaddechagasbasadasentransialidasa
AT perezanarosa desarrollopreclinicodevacunasprofilacticascontralaenfermedaddechagasbasadasentransialidasa
AT pacinimariaflorencia desarrollopreclinicodevacunasprofilacticascontralaenfermedaddechagasbasadasentransialidasa
first_indexed 2023-06-26T22:50:55Z
last_indexed 2023-06-26T22:50:55Z
_version_ 1769807392615170048

Ejemplares similares